The last few weekends have been roiled by headlines. Here's why we took a different direction on this medical stock this week ...

The stock's fall snapped a three-day winning streak.

Chairman and CEO of Abbott Laboratories (NYSE:ABT), recently sold a significant portion of his holdings in the company. According to a Form 4 filing with the Securities and Exchange Commission, Ford ...

His fears were that Abbott (NYSE:ABT) might pull the product entirely rather than risk further lawsuits—just like Johnson & ...

North Chicago, Illinois-based Abbott Laboratories (ABT) discovers, develops, manufactures, and sells healthcare products. Valued at $229.1 billion by market ... covering ABT stock, the ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS increase.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $75.0 to $135.0 for Abbott Laboratories over the last 3 months.

The company has a market cap of $222.36 billion ... 75.18% of the stock is owned by institutional investors. Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures ...